Five Prime Therapeutics, Inc. (FPRX)
(Delayed Data from NSDQ)
$11.55 USD
+0.51 (4.62%)
Updated May 3, 2019 04:00 PM ET
After-Market: $11.54 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.55 USD
+0.51 (4.62%)
Updated May 3, 2019 04:00 PM ET
After-Market: $11.54 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Biotech Stock Roundup: AMGN's Acquisition, ACAD's Regulatory Update & More
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Amgen (REGN), Acadia (ACAD) and Gilead (GILD).
Why Five Prime Therapeutics (FPRX) Might Surprise This Earnings Season
by Zacks Equity Research
Five Prime Therapeutics (FPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Amgen (AMGN) to Add Stomach Cancer Drug With Five Prime Buyout
by Zacks Equity Research
Amgen (AMGN) inks a $1.9-billion deal to acquire clinical-stage biotech, Five Prime Therapeutics, to boost its oncology pipeline.
ETFs to Tap Amgen's Drive for Cancer Deal
by Sweta Killa
Amgen (AMGN) has agreed to buy Five Prime Therapeutics (FPRX) for $1.9 billion.
Five Prime Therapeutics (FPRX) Stock Jumps 78.7%: Will It Continue to Soar?
by Zacks Equity Research
Five Prime Therapeutics (FPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Five Prime Therapeutics (FPRX) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Five Prime Therapeutics (FPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in Five Prime (FPRX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Five Prime (FPRX) stock based on the movements in the options market lately.
Five Prime Therapeutics (FPRX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of -21.31% and -41.49%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Five Prime Therapeutics (FPRX) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Five Prime Therapeutics (FPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Five Prime (FPRX) Looks Good: Stock Adds 5.1% in Session
by Zacks Equity Research
Five Prime (FPRX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Five Prime Therapeutics (FPRX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of 31.43% and -22.76%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Five Prime Therapeutics (FPRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Five Prime Therapeutics (FPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Five Prime Therapeutics (FPRX) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Five Prime Therapeutics (FPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Five Prime Therapeutics (FPRX) Stock a Solid Choice Right Now?
by Zacks Equity Research
Five Prime Therapeutics (FPRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Five Prime Therapeutics (FPRX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of 8.25% and -20.66%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Five Prime Therapeutics (FPRX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of -8.42% and -31.02%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Five Prime Therapeutics (FPRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Five Prime Therapeutics (FPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Five Prime Therapeutics (FPRX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of -15.12% and -39.71%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Five Prime Therapeutics (FPRX) Looks Good: Stock Adds 9.2% in Session
by Zacks Equity Research
Five Prime Therapeutics (FPRX) shares rose more than 9% in the last trading session, amid huge volumes.
Five Prime Therapeutics (FPRX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of 4.67% and -6.36%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Five Prime Therapeutics (FPRX) Q1 Earnings Expected to Decline
by Zacks Equity Research
Five Prime Therapeutics (FPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Five Prime Therapeutics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Five Prime Therapeutics.
MacroGenics Up on Lifting of Partial Hold on Cancer Candidate
by Zacks Equity Research
MacroGenics' (MGNX) shares rise as the FDA lifts partial clinical hold on its early-stage cancer candidate, MGD009, placed in December last year.
Five Prime Therapeutics, Inc. (FPRX) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Five Prime Therapeutics, Inc. (FPRX).
Five Prime Therapeutics (FPRX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of -17.09% and -22.56%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?